These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17194614)

  • 1. Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.
    Meyer O; de Bandt M; Berthelot JM; Cantagrel A; Combe B; Fautrel B; Flipo RM; Lioté F; Maillefert JF; Saraux A; Wendling D; Guillemin F; Le Loët X;
    Joint Bone Spine; 2007 Jan; 74(1):73-8. PubMed ID: 17194614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology.
    Le Loët X; Berthelot JM; Cantagrel A; Combe B; De Bandt M; Fautrel B; Flipo RM; Lioté F; Maillefert JF; Meyer O; Saraux A; Wendling D; Guillemin F
    Ann Rheum Dis; 2006 Jan; 65(1):45-50. PubMed ID: 15994280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept for the treatment of rheumatoid arthritis.
    Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
    van Vollenhoven RF; Chatzidionysiou K
    Nat Rev Rheumatol; 2013 Sep; 9(9):510-2. PubMed ID: 23897440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
    Kremer JM
    Ann Intern Med; 2001 Apr; 134(8):695-706. PubMed ID: 11304108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the medical management of rheumatoid arthritis.
    Scott DL
    Hosp Med; 2002 May; 63(5):294-7. PubMed ID: 12066349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab.
    Luong BT; Chong BS; Lowder DM
    Ann Pharmacother; 2000 Jun; 34(6):743-60. PubMed ID: 10860137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease modification in rheumatoid arthritis with leflunomide.
    Emery P
    Scand J Rheumatol Suppl; 1999; 112():9-14. PubMed ID: 10668522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
    N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
    Sizova L
    Br J Clin Pharmacol; 2008 Aug; 66(2):173-8. PubMed ID: 18537958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.